A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

Name: A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
License: Public Domain

GlaxoSmithKline

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

non

lung cancer, non-small cell

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 451521
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.